🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Brian Hemendra Ramnaraign

University of Florida Health

ORCID: 0000-0003-4051-4551

Also affiliated with University of Florida

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma”.

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma

Future Oncology(2023)10.2217/fon-2023-0256

N/A

0.399DataRank · unranked

4 citations

Sherise C. Rogers, Ji‐Hyun Lee, Brian Hemendra Ramnaraign, İlyas Şahin, Jesus C. Fabregas +11 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096

N/A

0.373DataRank · unranked

11 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps515

N/A

0DataRank · unranked

9 citations

Katherine A. Guthrie, Syed A. Ahmad, M. Kay Washington, Brian Hemendra Ramnaraign, Nitya Raj +8 more